
CELMoDs for the treatment of non-Hodgkin lymphoma
During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma.
This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.
Prior to the discussion, Salles presented an overview of CELMoDs, highlighting their mechanism of action and introducing golcadomide as a novel agent under investigation for lymphomas. He reviewed…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.